<meta http-equiv="content-type" content="text/html; charset=ISO-8859-1" />
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" >
<br>Title: Cost-effectiveness of Fluticasone Propionate/Salmeterol (250/50mcg) Compared to Salmeterol (50mcg)</br><br>Author: Christopher Blanchette, Director, CPOR, Lovelace Respiratory Research Institute, PO Box 760, Davidson, NC, 28036, United States of America, cblanchette@lrri.org</br><br>Coauthor(s): Harris Silver, Hans Petersen, Meaghan St. Charles</br><br>Year: 2008</br><br>Abstract: Bootstrapping methods were assessed to provide population-based parameter estimates for a cost-effectiveness analysis of Fluticasone Propionate/Salmeterol 250/50mcg (FSC) compared to Salmeterol 50mcg (SAL) from a trial based economic analysis using incremental cost-effectiveness ratios (ICER).</br>